Clinical Research Directory
Browse clinical research sites, groups, and studies.
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Sponsor: Instituto Nacional de Enfermedades Respiratorias
Summary
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Official title: Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2023-08-01
Completion Date
2025-09-01
Last Updated
2024-11-19
Healthy Volunteers
No
Conditions
Locations (1)
Center for Research in Infectious Diseases (CIENI)
Mexico City, Tlalpan, Mexico